AstraZeneca Targets $1.5 Billion in Annual Savings After Quarterly Revenue Rises 7%

AstraZeneca announced a restructuring programme on Friday, October 30, aimed at generating approximately $1.5 billion in annual pre-tax savings that it intends to direct largely toward developing new medicines. The company said the initiative could incur up to $2 billion in one-time charges and should be substantially completed by the end of 2029.

The announcement accompanied stronger third-quarter financial results. Revenue for the July–September 2026 period reached $16.209 billion, up 7% at constant exchange rates from a year earlier. The company's core earnings per share, an adjusted measure excluding specified items, increased 19% at constant exchange rates to $2.79. Reported earnings per share were $2.02, a different measure that includes items excluded from core earnings.

AstraZeneca maintained its 2026 guidance for revenue growth in the mid-to-high single digits and core earnings-per-share growth in the low double digits, both at constant exchange rates. The guidance is a projection, not a completed result for the year.

The company reported growth across cancer medicines, respiratory and immunology treatments, and rare-disease therapies. Those areas helped offset pressure from generic competition affecting older products, including Farxiga and Brilinta. Management has continued to invest in research and late-stage clinical trials as it seeks to maintain growth after some existing medicines lose patent protection.

The restructuring plan is intended to free resources for that pipeline, but AstraZeneca has not established how many employees, if any, will be affected. The projected $1.5 billion is an annualised savings target rather than money already saved, and the programme's timing and final costs remain subject to implementation.

Chief executive Pascal Soriot has reiterated the company's longer-term ambition of reaching $80 billion in annual revenue by 2030. That goal depends on future commercial performance, drug approvals and clinical-trial results, and should not be treated as guaranteed revenue.